March 28th 2024
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Safety Profile Remains Consistent When Darolutamide Is Added to ADT for nmCRPC
September 26th 2021Acceptable safety was noted with the addition of darolutamide to androgen deprivation therapy and resulted in infrequent extra adverse effects versus placebo in men with nonmetastatic castration-resistant prostate cancer.
The Addition of Olaparib to Abiraterone Yielded Positive High-Level Data in Frontline mCRPC
September 24th 2021Patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations may derive benefit from olaparib and abiraterone acetate, according data from the phase 3 PROpel trial.
Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial
Drs Brian Helfand and Steven Finkelstein share key takeaways and clinical pearls from the phase 2/3 EMPIRE-1 trial for prostate cancer.
Episodic Memory Improves With Darolutamide Vs Enzalutamide in Men With mCRPC
September 16th 2021Results from the phase 2 ODEZA trial comparing patient preference of antiandrogen agents indicates benefits of darolutamide over enzalutamide in terms of certain cognitive functions in men with metastatic castration-resistant prostate cancer.
Phase 2/3 EMPIRE-1 Trial in Prostate Cancer
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, review results from the phase 2/3 EMPIRE-1 trial examining the use of ¹⁸F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy for prostate cancer.